Search
12/01/2026
Biomarkers for Predicting Malignant Transformation of Premalignant Lesions of the Larynx: A Systematic Review
Rodrigo, JP, de Lima-Souza, RA, López, F, Stenman, G, Agaymy, A, Quer, M, Paleri, V, Leivo, I, Nadal, A, Zidar, N, Mariano, FV, Hellquist, H, Gale, N, Ferlito, A. Biomarkers for Predicting Malignant Transformation of Premalignant Lesions of the Larynx: A Systematic Review. Diagnostics. 2026; 16(2)DOI:10.3390/diagnostics16020236. PMID:41594212. IF:3.300(Q1/2D).
01/01/2026
Standardization of Sinonasal Anatomical Terminology in Spanish: An Expert Consensus
Villatoro-Sologaistoa, JC, Villatoro-Sologaisto, JC, Casasayas-Plass, M, Martel-Martin, M, Alfonso-Carrillo, C, Armengot-Carceller, M, Dominguez-Sosa, MS, Fernandez-Liesa, R, Garcia-Lliberós, A, Gil-Melcón, M, González-Compta, X, López-Alvarez, F, López-Chacón, M, Lobo-Duro, D, Mata-Castro, N, Monjas-Cánovas, I, Moreno-Luna, R, Pardo-Muñoz, L, Pinilla-Urraca, M, Santamaría-Gadea, A, Santos-Pérez, J, Valcárcel-Martin, F, Villacampa-Aubá, JM, del Cuvillo-Bernal, A, Sánchez-Gómez, S, Massegur-Solench, H, Bernal-Sprekelsen, M, Alobid, I. Standardization of Sinonasal Anatomical Terminology in Spanish: An Expert Consensus. Acta Otorrinolaringologica Espanola. 2026; 77(1)DOI:10.1016/j.otorri.2025.512275. PMID:. IF:(Q/D).
12/02/2024
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.. HAEMATOLOGICA. 2024; 109(2)DOI:10.3324/haematol.2023.283342. PMID:37560813. IF:10.100(Q1/2D).
15/01/2024
Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
Piñana JL, Tridello G, Xhaard A, Wendel L, Montoro J, Vazquez L, Heras I, Ljungman P, Mikulska M, Salmenniemi U, Perez A, Kröger N, Cornelissen JJ, Sala E, Martino R, Geurten C, Byrne J, Maertens J, Kerre T, Martin M, Pascual MJ, Yeshurun M, Finke J, Groll AH, Shaw PJ, Blijlevens N, Arcese W, Ganser A, Suarez-Lledo M, Alzahrani M, Choi G, Forcade E, Paviglianiti A, Solano C, Wachowiak J, Zuckerman T, Bader P, Clausen J, Mayer J, Schroyens W, Metafuni E, Knelange N, Averbuch D, de la Camara R. Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.. JOURNAL OF INFECTIOUS DISEASES. 2024; 229(1)DOI:10.1093/infdis/jiad268. PMID:37440459. IF:4.500(Q1/2D).
28/11/2023
Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: a CIBMTR analysis.
Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik MM, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan EA, Daly A, Dholaria B, Diaz MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi P, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Solh MM, Solomon SR, Ulrickson ML, Ustun C, van der Poel MWM, Verdonck LF, Wagner JL, Wang TP, Wirk B, Zeidan AM, Litzow MR, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: a CIBMTR analysis.. Blood Advances. 2023; 7(22)DOI:10.1182/bloodadvances.2023011308. PMID:37792849. IF:7.400(Q1/2D).
14/11/2023
Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a Phase 3b trial.
Sierra J, Montesinos P, Thomas X, Griskevicius L, Cluzeau T, Caillot D, Legrand O, Minotti C, Luppi M, Farkas F, Bengoudifa BR, Gilotti G, Hodzic S, Rambaldi A, Venditti A. Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a Phase 3b trial.. Blood Advances. 2023; 7(21)DOI:10.1182/bloodadvances.2023009847. PMID:37581981. IF:7.400(Q1/2D).